We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Prospective, Randomized, Controlled, Un-blinded, Multi-Center Clinical Trial to Evaluate the HeartWare® Ventricular Assist System for Destination Therapy of Advanced Heart Failure (ENDURANCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01166347
Recruitment Status : Completed
First Posted : July 21, 2010
Last Update Posted : September 25, 2017
Information provided by (Responsible Party):
HeartWare, Inc.

Brief Summary:
The purpose of this study is to determine the safety and effectiveness of the HeartWare Ventricular Assist System in patients with chronic Stage D/NYHA Class IIIB/IV left ventricular failure who have received and failed optimal medical therapy, and who are ineligible for cardiac transplantation.

Condition or disease Intervention/treatment
Chronic Heart Failure Device: HeartWare® VAS Device: Control LVAD

Detailed Description:
The HeartWare Ventricular Assist System (VAS) is intended for use in patients with chronic Stage D/NYHA Class IIIB/IV left ventricular failure who have received and failed optimal medical therapy and who are ineligible for cardiac transplantation. The ENDURANCE clinical study is a prospective, randomized, unblinded, multi-center, non-inferiority evaluation of the HeartWare® VAS versus a control group consisting of any FDA-approved LVAD approved for destination therapy. Patients are randomized to HeartWare® VAS or control LVAD in a 2:1 ratio. Each patient receiving the HeartWare® VAS or control LVAD is followed to the primary endpoint at 2 years, with a subsequent follow-up period extending to 5 years post implant.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 451 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Controlled, Un-blinded, Multi-Center Clinical Trial to Evaluate the HeartWare® Ventricular Assist System (VAS) for Destination Therapy of Advanced Heart Failure
Study Start Date : August 2010
Primary Completion Date : May 2014
Study Completion Date : May 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
U.S. FDA Resources

Arm Intervention/treatment
Experimental: HeartWare® VAS
Implant of HeartWare® Ventricular Assist System
Device: HeartWare® VAS
The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
Active Comparator: Control LVAD
Implant of FDA-approved LVADs approved for destination therapy
Device: Control LVAD
Any FDA-approved LVAD for destination therapy.

Primary Outcome Measures :
  1. Stroke-free survival [ Time Frame: Two years ]
    The primary endpoint of the trial is stroke-free survival at two years, defined as alive on the originally implanted device, transplanted or explanted due to patient recovery. Secondary endpoints include adverse events such as bleeding and infection, as well as functional status, hospitalization, assessment of neuro-cognitive function and patient quality of life.

Secondary Outcome Measures :
  1. Incidence of bleeding [ Time Frame: Two years ]
    Incidence of bleeding, per INTERMACS definition

  2. Incidence of major infections [ Time Frame: Two years ]
    Incidence of major infections, per INTERMACS definition

  3. Incidence of all device failures and device malfunctions [ Time Frame: Two years ]
    Incidence of all device failures and device malfunctions per INTERMACS definition

  4. Time to death [ Time Frame: Two Years ]
  5. Health Status improvement measured by KCCQ and EuroQol EQ-5D [ Time Frame: Two Years ]
    Health Status improvement as measured by Kansas City Cardiomyopathy Questionaire (KCCQ) and EuroQol EQ-5D.

  6. Functional status improvement measured by (NYHA)class and 6-minute walk [ Time Frame: Two Years ]
    Functional status improvement, as measured by New York Heart Association (NYHA)class and 6-minute walk test.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Must be ≥18 years of age at consent
  2. Body Surface Area (BSA) ≥ 1.2 m2
  3. Patients with advanced heart failure symptoms (Class IIIB or IV) who are: (patient must meet one of the following) 3a. On optimal medical management, including dietary salt restriction and diuretics, for at least 45 out of the last 60 days and are failing to respond; or 3b. In Class III or Class IV heart failure for at least 14 days, and dependent on intra aortic balloon pump (IABP) for 7 days and/or inotropes for at least 14 days
  4. Left ventricular ejection fraction (less than or equal to) 25%
  5. LVAD implant is intended as destination therapy
  6. Must be able to receive either the HeartWare® VAS or control LVAD
  7. Female patients of childbearing potential must agree to use adequate contraceptive precautions for the duration of the study.
  8. The patient or legally authorized representative has signed the informed consent form

Exclusion Criteria:

  1. Body Mass Index (BMI) > 40
  2. Existence of any ongoing mechanical circulatory support (MCS) other than an intra-aortic balloon pump (IABP)
  3. Prior cardiac transplant.
  4. History of confirmed, untreated abdominal or thoracic aortic aneurysm > 5 cm.
  5. Cardiothoracic surgery within 30 days of randomization.
  6. Acute myocardial infarction within 14 days of implant
  7. Patients eligible for cardiac transplantation
  8. On ventilator support for > 72 hours within the four days immediately prior to randomization and implant.
  9. Pulmonary embolus within three weeks of randomization
  10. Symptomatic cerebrovascular disease, stroke within 180 days of randomization or > 80% stenosis of carotid or cranial vessels.
  11. Uncorrected moderate to severe aortic insufficiency. Correction may include repair or bioprosthesis at the time of implant.
  12. Severe right ventricular failure as defined by the anticipated need for right ventricular assist device (RVAD) support or extracorporeal membrane oxygenation (ECMO) or right atrial pressure > 20 mmHg on multiple inotropes, right ventricular ejection fraction (RVEF) <15% or clinical signs
  13. Active, uncontrolled infection diagnosed by a combination of clinical symptoms and laboratory testing.
  14. Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelet count < 75,000, INR > 2.0 or PTT > 2.5 times control in the absence of anticoagulation therapy).
  15. Intolerance to anticoagulant or antiplatelet therapies or any other peri- or postoperative therapy that the investigator may administer based upon the patient's health status.
  16. Serum creatinine > 3.0 mg/dL within 72 hours of randomization or requiring dialysis (does not include use of ultra-filtration for fluid removal).
  17. All three liver enzymes [AST (SGOT), ALT (SGPT), or LDH] > 3 times upper limit of normal or a total bilirubin > 3 mg/dl within 72 hours of randomization, or biopsy proven liver cirrhosis or portal hypertension.
  18. Pulmonary vascular resistance is demonstrated to be unresponsive to pharmacological manipulation and the PVR > 6 Wood units.
  19. Patients with a mechanical heart valve .
  20. Etiology of heart failure is due to, or associated with, uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, active myocarditis or restrictive cardiomyopathy
  21. History of severe COPD or severe restrictive lung disease
  22. Participation in any other study involving investigational drugs or devices
  23. Severe illness, other than heart disease, which would limit survival to < 3 years
  24. Peripheral vascular disease with rest pain or ischemic ulcers of the extremities
  25. Pregnancy
  26. Patient unwilling or unable to comply with study requirements
  27. Technical obstacles, which pose an inordinately high surgical risk, in the judgment of the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01166347

  Hide Study Locations
United States, Alabama
The University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
United States, Arizona
Mayo Clinic Hospital - Phoenix
Phoenix, Arizona, United States, 85054
United States, California
The University of Southern California
Los Angeles, California, United States, 90033
Cedars Sinai Medical Center
Los Angeles, California, United States, 90048
Sharp Memorial
San Diego, California, United States, 92123
Stanford University School of Medicine
Stanford, California, United States, 94305
United States, Colorado
University of Colorado Hospital - Leprino
Aurora, Colorado, United States, 80045
United States, District of Columbia
Washington Hospital Center
Washington, D.C., District of Columbia, United States, 20010
United States, Florida
University of Florida - Gainesville
Gainesville, Florida, United States, 32610
University of Miami/Jackson Memorial Hospital
Miami, Florida, United States, 33136
Tampa Transplant Institute/Tampa General Hospital
Tampa, Florida, United States, 33606
United States, Georgia
The Emory Clinic Inc.
Atlanta, Georgia, United States, 30322
Saint Joseph Hospital of Atlanta
Atlanta, Georgia, United States, 30342
United States, Illinois
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611
University of Chicago
Chicago, Illinois, United States, 60637
Cardiothoracic & Vascular Surgical Associates
Oak Lawn, Illinois, United States, 60453
United States, Indiana
IU Health Methodist
Indianapolis, Indiana, United States, 46202
Saint Vincent Health
Indianapolis, Indiana, United States, 46260
United States, Kentucky
Jewish Hospital
Louisville, Kentucky, United States, 40202
United States, Louisiana
John Ochsner Heart & Vascular Institute
New Orleans, Louisiana, United States, 70115
United States, Maryland
University of Maryland
Baltimore, Maryland, United States, 21201
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Tufts Medical Center
Boston, Massachusetts, United States, 02111
United States, Michigan
University of Michigan Hospital
Ann Arbor, Michigan, United States, 48109
Henry Ford Hospital
Detroit, Michigan, United States, 48202
United States, Minnesota
Abbott Northwestern
Minneapolis, Minnesota, United States, 55407
University of Minnesota
Minneapolis, Minnesota, United States, 55455
St. Mary's Hospital
Rochester, Minnesota, United States, 55902
United States, Missouri
Washington University/Barnes-Jewish Hospital
Saint Louis, Missouri, United States, 63110
United States, New Jersey
Newark Beth Israel Medical Center
Newark, New Jersey, United States, 07112
United States, New York
New York Presbyterian Hospital/Columbia
New York, New York, United States, 10032
Montefiore Medical Center
The Bronx, New York, United States, 10467
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Ohio State University Medical Center
Columbus, Ohio, United States, 43210
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239
United States, Pennsylvania
Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, United States, 19104
UPMC Presbyterian
Pittsburgh, Pennsylvania, United States, 15213
United States, Texas
Baylor University Medical Center
Dallas, Texas, United States, 75246
University of Texas - South Western
Dallas, Texas, United States, 75390
Texas Heart Institute
Houston, Texas, United States, 77030
The Methodist Hospital
Houston, Texas, United States, 77030
United States, Utah
Intermountain Medical Center
Murray, Utah, United States, 84107
University of Utah
Salt Lake City, Utah, United States, 84132
United States, Virginia
Innova Heart and Vascular Institute Research - Cardiac Vascular & Thoracic Surgery Associates, PC
Falls Church, Virginia, United States, 22042
Sentara Norfolk
Norfolk, Virginia, United States, 23507
United States, Washington
University of Washington Medical Center
Seattle, Washington, United States, 98195
Northwest Cardiothoracic &Transplant Surgeons
Spokane, Washington, United States, 99204
United States, Wisconsin
Saint Luke's Medical Center
Milwaukee, Wisconsin, United States, 53215
Sponsors and Collaborators
HeartWare, Inc.
Principal Investigator: Francis Pagani, MD University of Michigan Hospital
Principal Investigator: Joseph Rogers, MD Duke University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: HeartWare, Inc.
ClinicalTrials.gov Identifier: NCT01166347     History of Changes
Other Study ID Numbers: HW004 ENDURANCE
First Posted: July 21, 2010    Key Record Dates
Last Update Posted: September 25, 2017
Last Verified: September 2017

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases